SCHEMBL4569342

SCHEMBL4569342

C[C@H](Nc1ccnc2ccnn12)c1cc2cccc(Cl)c2c(CCN2CCOCC2)n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNN3 Q9UGI6 1/20 0.36
ALDH1A1 P00352 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C19 P33261 1/20 0.35
CLK4 Q9HAZ1 1/20 0.35
PIK3CD O00329 3/20 0.34
PIK3R2 O00459 2/20 0.34
PIK3CG P48736 1/20 0.33
PIK3R1 P27986 1/20 0.33
SIGMAR1 Q99720 1/20 0.32
AVPR1B P47901 4/20 0.32
MAPK13 O15264 2/20 0.32
MAPK12 P53778 2/20 0.32
MAPK10 P53779 2/20 0.32
MAPK11 Q15759 2/20 0.32
MAPK14 Q16539 2/20 0.32
MAPK8 P45983 1/20 0.32
CHRM2 P08172 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4569389 0.80 HTR2C (0.38) KCNN3CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL4569369 0.80 KCNN3 (0.36) KCNN3CYP3A4CYP2D6CYP2C19PIK3CD
SCHEMBL4569361 0.79 KCNN3 (0.38) KCNN3CYP1A2CYP3A4CYP2D6PIK3CD
SCHEMBL16269981 0.78 PIK3CD (0.38) ALDH1A1PIK3CDPIK3R2PIK3CGAVPR1B
SCHEMBL4569343 0.77 PIK3CD (0.47) CYP1A2CYP3A4CYP2D6CLK4PIK3CD
SCHEMBL4535138 0.77 SIGMAR1 (0.41) PIK3CDPIK3R2PIK3CGSIGMAR1AVPR1B
SCHEMBL3695237 0.77 SIGMAR1 (0.41) PIK3CDPIK3R2PIK3CGSIGMAR1AVPR1B
SCHEMBL4569391 0.77 PIK3CD (0.42) PIK3CDPIK3R2PIK3CGPIK3R1AVPR1B
SCHEMBL4569341 0.77 PIK3CD (0.45) ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL3705566 0.77 SYK (0.36) PIK3CDPIK3R2PIK3CGAVPR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9388183-B2 Heterocyclic compounds and uses thereof INFINITY PHARMACEUTICALS, INC. (US) 2016-07-12 US disclosed
US-9388183-B2 Heterocyclic compounds and uses thereof INFINITY PHARMACEUTICALS, INC. (US) 2016-07-12 US disclosed
US-20150031672-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF INFINITY PHARMACEUTICALS, INC. 2015-01-29 US disclosed
US-20150031672-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF INFINITY PHARMACEUTICALS, INC. 2015-01-29 US disclosed
US-8901133-B2 Heterocyclic compounds and uses thereof INFINITY PHARMACEUTICALS, INC. (US) 2014-12-02 US disclosed
US-8901133-B2 Heterocyclic compounds and uses thereof INFINITY PHARMACEUTICALS, INC. (US) 2014-12-02 US disclosed
WO-2012064973-A2 HETEROCYCLIC COMPOUNDS AND USES THEREOF INFINITY PHARMACEUTICALS, INC. (US) 2012-05-18 WO disclosed
US-20120122838-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF INFINITY PHARMACEUTICALS, INC. 2012-05-17 US disclosed
US-20120122838-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF INFINITY PHARMACEUTICALS, INC. 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150031672-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF PIK3CA, PIK3CD, PIK3CB KCNN3 1944/4885ALDH1A1 3154/4885CYP1A2 2099/4885
US-20120122838-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF PIK3CA, PIK3CD, PIK3CB KCNN3 1944/4885ALDH1A1 3154/4885CYP1A2 2099/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.